SecBot SecBot
SECBOTREPLAY Home › Report › DNLI

DNLI · Denali Therapeutics announced that Takeda has terminated their 2018…

Denali Therapeutics Inc. · 8-K filed Apr 3, 2026 at 14:43 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Apr 3, 2026 at 14:43 ET

Denali Therapeutics announced that Takeda has terminated their 2018 collaboration agreement to co-develop and co-commercialize DNL593 for frontotemporal dementia, citing strategic reasons unrelated to efficacy or safety. Denali will regain full rights to the program and continue its clinical development independently, with Phase 1/2 data expected by end of 2026.

  • Takeda terminated the 2018 collaboration agreement for DNL593 (PTV:PGRN) for FTD-GRN due to strategic considerations, not efficacy or safety issues
  • All rights to DNL593 will revert to Denali 60 days after the April 3, 2026 notice
  • Denali will have no further financial obligations to Takeda post-termination
  • Denali plans to continue clinical development of DNL593 independently

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access